Aaron Weiner
Boston, Massachusetts, United States
10K followers
500+ connections
10K followers
500+ connections
About
I build talent solutions that help biotech and life sciences companies grow stronger…
Activity
10K followers
-
Aaron Weiner shared this🧠 Share this one with your favorite neuron lover 🧠Aaron Weiner shared thisDo you or someone you know ❤️ neurons? Merge Labs is recruiting a Neuron Whisperer! 🧠 🤗 https://lnkd.in/gA8gf-qF Merge Labs is building high-bandwidth molecular BCIs, is based in the SF Bay area, and is backed with $250M+ from OpenAI and others.
-
Aaron Weiner shared thisI've been lucky to support the team at Merge Labs as they build something special - both in the frontier research and the people. Ambitious goals, real ownership, and a level collaboration I haven't seen before. Check out merge.io/careers for additional roles, or feel free to reach out directly.Aaron Weiner shared thisFun to watch the team at Merge Labs grow in size and talent. 💪 Actively recruiting roles include: 🧬 De novo design, bayesian optimization and ML ops - tackle problems that require inventing new computational protein eng & synbio approaches 🧪 Immunology - figure out how to tolerize novelty 🥼 Lab ops associate - make the lab and the science hum (symphonically) ⚡ We're always recruiting talented Research Associates seeking to learn and grow, and are willing to bet on potential. Merge Labs is based in the SF Bay area and backed with $250M+ from OpenAI and others. Full JDs and applications at merge.io/careers.
-
Aaron Weiner reposted thisAaron Weiner reposted this🎉 Asimov is hiring a Head of Finance! We are looking for a strategic and forward thinking Head of Finance to join our team and help scale our financial infrastructure as we accelerate innovation in synthetic biology. We're looking for someone who thrives in a fast-paced, collaborative environment, brings strong financial rigor, and has a track record of leadership in high-growth companies. If you're interested or know someone who'd be a great fit, please reach out! #hiring #finance #biotech #biotechcareers
-
Aaron Weiner reposted thisWe are hiring!!! Ready to make an impact? Apply to the link below #Hiring #CBO #Biotech #BostonJobs #VentureBuilder #CellAndGeneTherapyAaron Weiner reposted thisWe are looking for a Chief Business Officer to help shape and scale Volnay and its next generation of cell- and gene-therapy ventures. We are a highly collaborative, purpose-driven company, where you can help drive strategy, partnerships, and company creation. #celltherapy #venture creation #CBO
-
Aaron Weiner reposted thisAaron Weiner reposted thisNew Role Alert! - Boston Health AI Is Hiring a Chief Technology Officer One of C10 Labs’ fastest-rising portfolio companies — Boston Health AI — is opening a rare, high-impact CTO role to help build the future of clinical AI. Boston Health AI is already redefining care delivery across 7 hospitals, 16 specialties, and 15,000+ patient encounters with Hami, an AI physician assistant that listens, reasons, documents, codes, educates, and connects — all through a multilingual, empathic interface powered by a next-generation multi-agent architecture. Now we’re scaling globally and we’re looking for a technical leader who can help take this from a powerful platform to a category-defining clinical AI system. C10 Labs Boston Health AI Adil Haider #ai #CTO https://lnkd.in/eaWuACYY
-
Aaron Weiner reposted thisHey guys, I don't really share too much on LinkedIn but wanted to bring to your attention that we started to sell our product, Synecta T1, for the activation of T cells. It is a promising, easy to use product that allows faster activation for production of high quality T cells at shorter amount of time and without the usage of soluble cytokines. We are working on all fronts to make sure it will be an easy transition for any company that wants to adapt our product. Below you see an example of one action we took on the regulatory front to allow quick regulatory adaptation. One other action on that front is the on-going phase I clinical trail (looks very promising). On the supply chain side, we are working on a GMP production with our new strategic partner, Avantor. Please let us know if you want to learn more.Aaron Weiner reposted thisThe Synecta platform has received FDA Advanced Manufacturing Technology (AMT) designation, recognizing it as a next-generation approach that supports reliable, high-quality, and scalable engineered T-cell manufacturing. Synecta provides a physiological, membrane-bound activation method designed to streamline workflows and support manufacturing as programs progress toward clinical and commercial scale. For developers, the AMT designation enables earlier, more frequent interaction with the FDA, supporting efficient progression into late-stage and commercial manufacturing. Read our full press release: https://lnkd.in/ehvxEZpC #CellTherapy #AMTDesignation #FDA #Synecta
-
Aaron Weiner reposted thisAaron Weiner reposted thisThe Synecta platform has received FDA Advanced Manufacturing Technology (AMT) designation, recognizing it as a next-generation approach that supports reliable, high-quality, and scalable engineered T-cell manufacturing. Synecta provides a physiological, membrane-bound activation method designed to streamline workflows and support manufacturing as programs progress toward clinical and commercial scale. For developers, the AMT designation enables earlier, more frequent interaction with the FDA, supporting efficient progression into late-stage and commercial manufacturing. Read our full press release: https://lnkd.in/ehvxEZpC #CellTherapy #AMTDesignation #FDA #Synecta
-
Aaron Weiner shared this⏳ Time and runway have never been more under the microscope in this industry than they are right now. Building a performance management system in biotech startup isn't just about checking boxes and reviews...it's about aligning science, strategy, and people to make the most of their time and contributions. In our collaboration with BlueWhale Bio, we created and rolled out a scalable performance management system that fits their scientific culture, sets clear expectations, and supports growth. 🏁 The results? A smooth review cycle, better manager-employee alignment, and a strong foundation for career development. Check out what CEO, Peter Keller had to say... “The performance system we implemented with AK Bio has been a game changer, it helps us hire people who truly fit our culture, set clear goals at both the team and individual level, and retain the talent that drives our science forward. It’s also helped us right-size our teams more effectively and reduce recruiting costs while supporting both talent and investor attraction, demonstrating that we’re intentional and thoughtful about building a scalable company.” -- If you're building a biotech company and wondering when or how to put structure around performance, happy to share what worked or hear what's working for you.
-
Aaron Weiner liked thisAaron Weiner liked this𝗕𝗹𝘂𝗲𝗪𝗵𝗮𝗹𝗲 𝗕𝗶𝗼 𝗶𝘀 𝗲𝘅𝗽𝗮𝗻𝗱𝗶𝗻𝗴 𝗮𝗰𝗰𝗲𝘀𝘀 𝘁𝗼 𝗦𝘆𝗻𝗲𝗰𝘁𝗮™ 𝗧𝟭 𝗮𝗰𝗿𝗼𝘀𝘀 𝗘𝘂𝗿𝗼𝗽𝗲 𝘁𝗵𝗿𝗼𝘂𝗴𝗵 𝗮 𝗻𝗲𝘄 𝗽𝗮𝗿𝘁𝗻𝗲𝗿𝘀𝗵𝗶𝗽 𝘄𝗶𝘁𝗵 Tebubio. Europe has long been a center of excellence for cell and gene therapy research. As more programs move toward clinical development and commercialization, the focus is increasingly extending beyond therapeutic design to a critical question: 𝗛𝗼𝘄 𝗰𝗮𝗻 𝗮𝗱𝘃𝗮𝗻𝗰𝗲𝗱 𝗰𝗲𝗹𝗹 𝘁𝗵𝗲𝗿𝗮𝗽𝗶𝗲𝘀 𝗯𝗲 𝗺𝗮𝗻𝘂𝗳𝗮𝗰𝘁𝘂𝗿𝗲𝗱 𝗺𝗼𝗿𝗲 𝘀𝗶𝗺𝗽𝗹𝘆, 𝗰𝗼𝗻𝘀𝗶𝘀𝘁𝗲𝗻𝘁𝗹𝘆 𝗮𝗻𝗱 𝗲𝗳𝗳𝗶𝗰𝗶𝗲𝗻𝘁𝗹𝘆? Through this partnership, researchers and cell therapy developers across Europe will gain local access to Synecta, supported by Tebubio’s network of scientific and application specialists. 𝗙𝗶𝗻𝗱 𝘆𝗼𝘂𝗿 𝗹𝗼𝗰𝗮𝗹 𝗱𝗶𝘀𝘁𝗿𝗶𝗯𝘂𝘁𝗼𝗿: https://lnkd.in/gHcp7RYA #CellTherapy #ATMP #CellManufacturing #CART #TCellTherapy #Synecta
-
Aaron Weiner liked thisAaron Weiner liked thisCongratulations to our resident company, Nava Therapeutics, on emerging from stealth mode with $89 million in financings to advance its lipid nanoparticle (LNP) platform. Nava is tackling one of the biggest challenges in genetic medicine: developing delivery technologies that can get therapies to the right cells and tissues. The company’s first focus is in vivo CAR-T, an emerging approach that aims to move beyond traditional cell therapy manufacturing by reprogramming T cells directly inside the body. Nava is also developing LNPs designed to target the kidney — an organ that has historically been difficult to reach with genetic medicines and could open new opportunities for treating diseases with limited options today. Congratulations to the entire Nava Therapeutics team! Full Endpoints News article: https://lnkd.in/gHQHHnVWExclusive: Lipid nanoparticle startup Nava emerges with $89M to target T cells and kidneyExclusive: Lipid nanoparticle startup Nava emerges with $89M to target T cells and kidney
-
Aaron Weiner liked thisAaron Weiner liked thisExcited to share that I've joined Biorce as a Talent Acquisition Partner, where I'll be focused on building our global commercial team. The opportunity to join an ambitious team building AI that's tackling one of the biggest bottlenecks in drug development was one I couldn't pass up. There's an incredible amount of innovation happening here, and I'm excited to help bring in the people who will shape the next phase of growth. A huge thank you to Sara Macedo, Pedro Coelho, and Dennis Velasquez for the opportunity. I'm excited to contribute to what we're building together. If you're passionate about AI, healthcare and innovative technology that can meaningfully accelerate trial development, message me! matthew.boldeau@biorce.com
-
Aaron Weiner liked thisAaron Weiner liked this4:59 is hiring an ML Engineer in drug discovery! We build models to guide decision-making on chemistry that hasn't been explored before. This role is about interfacing with ML research and developing models that advance real drug discovery programs. We're looking for strong experience with PyTorch + productionizing ML code; great engineering taste; and excitement in collaborating with experimental chemists & biologists. If that sounds exciting: https://lnkd.in/g7T-2Kt65AM Ventures - Machine Learning Engineer - Computational Drug Discovery5AM Ventures - Machine Learning Engineer - Computational Drug Discovery
-
Aaron Weiner liked thisAaron Weiner liked thisThis morning, I finished my last team meeting as Global Head of Regulatory Policy and Innovation at Takeda. The past five years have been incredible. Over this time, I worked closely with Nahid Latif to build and shape a team and function that I'm deeply proud of, grounded in a simple idea: regulatory policy isn't peripheral to product strategy—it is product strategy. We built the group around a philosophy we called "Policy for Impact": using policy deliberately, collaboratively, and proactively to create value for our pipeline and, ultimately, for patients. Together, we demonstrated what policy can achieve when it is approached strategically: • successfully challenging CRLs • transferring a Sakigake designation to unlock a new asset • securing the industry's first orphan designation for Narcolepsy Type 1 • meaningfully incorporating the patient voice into multiple rare disease applications • co-developing an AI-enabled platform with Weave.bio to accelerate multi-agency reviews And at the same time, we worked alongside colleagues through initiatives like the Charles Forum and PRISM to advance regulatory science. I've loved my time at Takeda. I'm especially grateful to Nahid Latif and Andy Plump for believing that policy could be a strategic differentiator and giving us the opportunity to prove it. One of the first things Andy ever said to me was, "I'm excited to see what Regulatory Policy can do for Takeda." That belief shaped much of what followed. And most of all, my team. To Kristin Van Goor, Jesus Muniz, Cameron Kieffer, PhD, Sini Eskola, Yuji Kashitani, Annette Schmid, PhD, Helene S., David Hampton, Matthew Raymond, PhD, Lindsay Cobbs, Rose Purcell, Anzhela Kukh, Patrick Mumo, Danni Shen, Rieko Wu and many others—thank you for your collaboration and creativity. Everything we accomplished was a reflection of your talent, dedication, and commitment to patients. Takeda has been a special chapter for me. I'll carry these experiences—and the relationships that came with them—with me into what comes next. #RegulatoryPolicy #PatientVoice #Innovation
-
Aaron Weiner liked this🚨FUNDED!!!!!!!🚨 ahhhhhhhhhhhhhhhhhhhhhh 🤩Aaron Weiner liked thisMay the grant gods bless Siren Biotechnology today y'all. Final committee vote on a big one 🙏
-
Aaron Weiner liked thisCongrats to two of my closest/longtime friends Han Kim and Kevin Bennett, and new friends like Angela Gao on launching Fearn AI! A Promethean effort to give inventors the power! 💪 Proud to be a tiny part of their story. Go team!Aaron Weiner liked thisToday we’re announcing Fearn’s $5.5M seed, led by Kindred Ventures, with a16z speedrun, Designer Fund, and Essence Venture Capital. Patent systems across the world are first-to-file. The priority date is everything. This means that inventors with elite in-house IP teams can file in 48 hours. Everyone else waits weeks. Those weeks are the difference between taking the speaking invitation and passing, between publishing and staying quiet, between closing the deal and watching it slip. We're cutting patent drafting from 50+ hours to 20 minutes, at a flat $2,000 per patent application—a cost reduction of up to 96% against the traditional model. Fearn is not a wrapper on a general-purpose model. We compose dozens of small models—some LLM-based, some built from scratch—engineered to resist hallucination and to produce drafts with formally verified guarantees against the failure modes that matter in prosecution, including written-description sufficiency under §112(a) and the figure-labeling requirements of §1.84(p)(5) and MPEP §608.01(g). No calls to outside AI. Every model is self-hosted. I spent years in Big Law drafting patents the traditional way. Innovation moves at one speed, protection moves at another. That mismatch is where inventors lose ground. We built Fearn to close it. If your IP spend is too high, or you’re tired of your engineers and scientists explaining their work to lawyers, try Fearn. No sales call required.
-
Aaron Weiner liked thisAaron Weiner liked thisRecruiters, see the new technology top firms use to automate reference checks. References respond in < 24 hours so you fill roles fast.
-
Aaron Weiner liked thisAaron Weiner liked thisStealth BioTherapeutics is hiring a Senior Medical Director. Please feel free to share this job posting with your network.
Experience
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Education
Volunteer Experience
-
Jimmy Fund Golf
Dana-Farber Cancer Institute
- Present 14 years 11 months
Health
Founding member of a team that organizes and runs an annual Jimmy Fund golf tournament that raises money for the Dana-Farber Cancer Institute.
Recommendations received
4 people have recommended Aaron
Join now to viewOther similar profiles
Explore top content on LinkedIn
Find curated posts and insights for relevant topics all in one place.
View top content